Skip to main content
Figure 5 | BMC Health Services Research

Figure 5

From: Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults

Figure 5

Sensitivity analysis of cost and the romiplostim dose. The treatment costs varied by 50% above and below the base case analysis, and the romiplostim dose varied from one to two vials. Broken lines denote the results of the difference in the cost-effectiveness ratios in the base case analysis. (a) Difference in the cost-effectiveness ratios between sequences 1 and 2. (b) Difference in the cost-effectiveness ratios between sequences 1 and 3.

Back to article page